2 results
Approved WMOPending
To evaluate the efficacy and safety of extended release (ER) Niacin/Laropiprant when added to ongoing lipid-modifying therapy in patients with primary hypercholesterolemia or mixed dyslipidemia.
Approved WMORecruiting
The first objective is to investigate whether biofeedback on HRV and voice volume will lead to a larger decrease of IPV compared to treatment as usual (CBT only). Second, to test the premise that IPV perpetrators have trouble self-observing bodily…